BIOTECHNOLOGY Stocks Expected To Be Up After Top Correlated Stocks Fire Buy Signals.

August 23, 2011 / M2 PRESSWIRE / BUYINS.NET / http://www.squeezetrigger.com is monitoring the top most highly correlated BIOTECHNOLOGY stocks and the majority have fired a Buy signal as of today. INCYTE CORP (NASDAQ:INCY), CEPHALON INC (NASDAQ:CEPH), POWERSHARES DYN BIOTECH&GENO (NYSE:PBE), BIOTECH HOLDRS TRUST (NYSE:BBH), CHARLES RIVER LABORATORIES (NYSE:CRL), ENZON PHARMACEUTICALS INC (NASDAQ:ENZN) are all expected to be Up as the top stocks in the sector have fired Buy signals. Group rotation is a phenomenon where institutions exert buying or selling pressure in an industry group, pushing prices of the group higher or higher relative to the general market. An industry can often lead or lag the market, and the most highly correlated stocks (mirror closest to the overall move in that group) usually move in unison. The technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php . The chart below displays the correlation, beta and relative strength of the top most highly correlated stocks in the highlighted industry group:

     Symbol     Company                             Correlation     Beta        RelStr      Sector 
     INCY       INCYTE CORP                         0.79            2.52        1.06        BIOTECHNOLOGY
     CEPH       CEPHALON INC                        0.36            0.34        0.97        BIOTECHNOLOGY
     PBE        POWERSHARES DYN BIOTECH&GENO        0.93            0.91        0.99        BIOTECHNOLOGY
     BBH        BIOTECH HOLDRS TRUST                0.82            0.19        1.02        BIOTECHNOLOGY
     CRL        CHARLES RIVER LABORATORIES          0.81            1.06        1.02        BIOTECHNOLOGY
     ENZN       ENZON PHARMACEUTICALS INC           0.82            1.16        0.99        BIOTECHNOLOGY

We automatically calculate correlation to help find the stocks that most closely match their groups movement and generate powerful group consensus trading signals to profit from the herd mentality. When multiple stocks in a group turn at the same time and the rotation of that group is confirmed, an explosive move typically occurs. Correlation measures the tendency for a symbol to move in unison with the group, beta measures the amount the symbol is expected to move relative to the group and relative strength looks back at the recent past to show how the stock has been moving relative to the group.

INCYTE CORP (NASDAQ:INCY) - Incyte Corporation focuses on the discovery and development of proprietary small molecule drugs for hematologic and oncology indications, and for chronic inflammatory and autoimmune diseases. Its product pipe line includes INCB18424, which is in Phase III clinical trial for myelofibrosis; Phase II trial for polycythemia vera/essential thrombocythemia; Phase I/II trial to treat other hematologic tumors; and Phase IIb trail for the treatment of psoriasis. The companys portfolio also includes INCB28050, a Phase II clinical trial product for rheumatoid arthritis; INCB28060, a Phase I product for solid cancers; INCB7839, a Phase II product for breast cancer; INCB24360, an IND cleared product for oncology; and INCB13739, a Phase IIb product to treat type 2 diabetes. It has a collaborative research and license agreements with Pfizer Inc.; Novartis International Pharmaceutical Ltd.; and Eli Lilly and Company. The company was founded in 1991 and is headquartered in Wilmington, Delaware.

CEPHALON INC (NASDAQ:CEPH) - Cephalon, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of products for central nervous system, inflammatory disease, pain, and oncology therapeutic areas. Its products for central nervous system disorders include PROVIGIL for the treatment of excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome, and shift work sleep disorder; NUVIGIL, a single-isomer formulation of modafinil; and GABITRIL for use as an adjunctive therapy in the treatment of partial seizures in epileptic patients. The companys pain therapeutics portfolio comprises AMRIX for the relief of muscle spasm associated with acute painful musculoskeletal conditions; and FENTORA, EFFENTORA, ACTIQ, and generic OTFC products, which focus on treating breakthrough cancer pain in opioid-tolerant patients. Its products for oncology consist of TREANDA, a bi-functional hybrid cytotoxic; TRISENOX, an intravenous arsenic-based targeted therapy; CEP-701, an oral small molecule tyrosine kinase inhibitor; MYOCET, a cardio-protective chemotherapy agent to treat metastatic breast cancer; TARGRETIN for the treatment of cutaneous T-cell lymphoma; and ABELCET, an anti-fungal product for cancer patients. The company provides its products principally to wholesale drug distributors. It has collaboration agreements with Euroscreen s.a.; Ligand Pharmaceuticals Incorporated; Psychogenics Inc.; and AMBIT Biosciences Inc, as well as a research agreement with Celator Pharmaceuticals Inc. Cephalon, Inc. markets its products primarily in the United States, Europe, the Middle East, and Africa. The company was founded in 1987 and is headquartered in Frazer, Pennsylvania.

POWERSHARES DYN BIOTECH&GENO (NYSE:PBE) - PWRSHR DYN BIO&GE

BIOTECH HOLDRS TRUST (NYSE:BBH) - Ml Biotech Hldr

CHARLES RIVER LABORATORIES (NYSE:CRL) - Charles River Laboratories International, Inc. provides research models and laboratory animal support expertise to help its global partners advance their research and drug development efforts. The company offers a portfolio of services to support discovery and imaging, preclinical and early-phase clinical studies, and biopharmaceutical and endotoxin products and services for manufacturing and quality control. Its portfolio spans the entire research and drug development process, from IND consultation to discovery through market approval, allowing customized approaches to support both single-study or broad-based programs. Charles River Laboratories International serves pharmaceutical and biotechnology companies, as well as government agencies, hospitals, and academic institutions. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

ENZON PHARMACEUTICALS INC (NASDAQ:ENZN) - Enzon Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for patients with cancer primarily in the United States and Europe. Its drug development program utilizes Customized Linker technology and the Locked Nucleic Acid technology. The companys development product pipeline consists of PEG-SN38 compound that utilizes PEGylation technology for the treatment of colorectal, breast, and pancreatic cancer, as well as for non-Hodgkins lymphoma; and hypoxia-inducible factor 1 alpha antagonist for the treatment of cancers, including common solid tumors. Its product line also comprises Survivin Antagonist that plays a regulatory role in both apoptosis and cell division. The company also licenses its PEGylation platform for various products, such as PEG-INTRON, Macugen, and CIMZIA. Enzon Pharmaceuticals, Inc. was founded in 1981 and is based in Bridgewater, New Jersey.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact:

BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net

N※N

BIOTECHNOLOGY Stocks Expected To Be Up After Top Correlated Stocks Fire Buy Signals.